Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an announcement.
Sonnet BioTherapeutics Holdings, Inc., a biotech firm specializing in oncology, has met Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. Despite this achievement, the company will be monitored for a year to maintain compliance. Sonnet focuses on developing targeted biologic drugs and is currently advancing several promising programs for cancer treatment, including collaborations with industry giants like Roche.
Learn more about SONN stock on TipRanks’ Stock Analysis page.
